Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07329322 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 50% 60 → 30 participants
See other at-risk trials from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Record History

  1. Enrollment reduced: 60 → 30 participants Trial arms changed: 2 → 1 · Study description shortened, about 5 words · Study title shortened, about 3 wordsv4 Show 3 more changesShow less
    • Trial arms changed: 2 → 1
    • Study description shortened, about 5 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv3
  3. Recruitment opened Start date changed from estimate of Feb 1, 2026 to Mar 30, 2026v2 Show 1 more changeShow less
    • Start date changed from estimate of Feb 1, 2026 to Mar 30, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Trial Details
NCT Number NCT07329322
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov